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Decreased Pain Sensitivity Among People with Schizophrenia: A Meta-
analysis of Experimental Pain Induction Studies 
Abstract 
Schizophrenia patients report reduced pain sensitivity in clinical studies, but experimental studies 
are required to establish pain sensitivity as a potential endophenotype.  We conducted a systematic 
review of electronic databases from database inception until 15/04/2015, including experimental 
studies investigating pain among schizophrenia-spectrum disorder patients versus healthy controls. 
A random effect meta-analysis  yielding  Hedges’  g  ±95%  confidence  intervals  (CIs)  as  the  effect  size  
measure (ES) was conducted. Primary outcome was a pooled composite of pain threshold, pain 
tolerance, and sensory threshold; secondary outcomes included these parameters individually, plus 
physiological pain response, and pain intensity/unpleasantness.  Across 17 studies, schizophrenia-
spectrum disorder patients (n=387, age=30.7±6.9 years, female=31.9%, illness duration=7.0±5.7 
years) were compared with controls (n=483, age=29.5±7.4 years, female=31.0%). Patients had 
elevated pain threshold/pain tolerance/sensory threshold versus controls (ES=0.493, 95% CI=0.145-
0.839, p=0.005; studies=17). Results were similar in antipsychotic-free individuals (ES=0.599, 95% 
CI=0.291-0.907, p<0.0001; studies=8), with trend-level significance in antipsychotic-treated 
individuals (ES=0.428, 95%CI=-0.059-0.915, p=0.085; studies=11). Likewise, schizophrenia patients 
had increased pain tolerance (ES=0.566, 95% CI=0.235-0.897, p=0.0001; studies=6), sensory 
threshold (ES=1.16, 95% CI=0.505-1.727, p<0.0001; studies=5) and pain threshold (ES=0.696, 95% CI 
0.407-0.986, p<0.001; studies=9), and reduced physiological response to painful stimuli (ES=0.456, 
95%CI=0.131-0.783, p=0.006) and pain intensity/unpleasantness ratings (ES=0.547, 95% CI=0.146-
0.949, p=0.008). Findings were similarly significant in antipsychotic-free schizophrenia patients 
(analyzable parameters=4) and antipsychotic-treated individuals (analyzable parameters=2). Finally, 
greater psychiatric symptoms and younger patient age moderated increased pain 
tolerance/threshold.  Decreased pain sensitivity seems to be an endophenotype of schizophrenia-
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spectrum disorders. How this alteration links to other dimensions of schizophrenia and physical 
comorbidity-related help-seeking behaviour/morbidity/mortality requires further study. 
Key words: schizophrenia, pain, experimental pain, physical health, pain assessment, pain 
management 
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Abstract 
Schizophrenia patients report reduced pain sensitivity in clinical studies, but experimental studies 
are required to establish pain sensitivity as a potential endophenotype.  We conducted a systematic 
review of electronic databases from database inception until 15/04/2015, including experimental 
studies investigating pain among schizophrenia-spectrum disorder patients versus healthy controls. 
A random effect meta-analysis  yielding  Hedges’  g  ±95% confidence intervals (CIs) as the effect size 
measure (ES) was conducted. Primary outcome was a pooled composite of pain threshold, pain 
tolerance, and sensory threshold; secondary outcomes included these parameters individually, plus 
physiological pain response, and pain intensity/unpleasantness.  Across 17 studies, schizophrenia-
spectrum disorder patients (n=387, age=30.7±6.9 years, female=31.9%, illness duration=7.0±5.7 
years) were compared with controls (n=483, age=29.5±7.4 years, female=31.0%). Patients had 
elevated pain threshold/pain tolerance/sensory threshold versus controls (ES=0.493, 95% CI=0.145-
0.839, p=0.005; studies=17). Results were similar in antipsychotic-free individuals (ES=0.599, 95% 
CI=0.291-0.907, p<0.0001; studies=8), with trend-level significance in antipsychotic-treated 
individuals (ES=0.428, 95%CI=-0.059-0.915, p=0.085; studies=11). Likewise, schizophrenia patients 
had increased pain tolerance (ES=0.566, 95% CI=0.235-0.897, p=0.0001; studies=6), sensory 
threshold (ES=1.16, 95% CI=0.505-1.727, p<0.0001; studies=5) and pain threshold (ES=0.696, 95% CI 
0.407-0.986, p<0.001; studies=9), and reduced physiological response to painful stimuli (ES=0.456, 
95%CI=0.131-0.783, p=0.006) and pain intensity/unpleasantness ratings (ES=0.547, 95% CI=0.146-
0.949, p=0.008). Findings were similarly significant in antipsychotic-free schizophrenia patients 
(analyzable parameters=4) and antipsychotic-treated individuals (analyzable parameters=2). Finally, 
greater psychiatric symptoms and younger patient age moderated increased pain 
tolerance/threshold.  Decreased pain sensitivity seems to be an endophenotype of schizophrenia-
spectrum disorders. How this alteration links to other dimensions of schizophrenia and physical 
comorbidity-related help-seeking behaviour/morbidity/mortality requires further study. 
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Introduction 
Research has consistently demonstrated that people with schizophrenia experience an 
increased number of painful physical health comorbidities, including fractures [48], diabetes [50] 
and cardiovascular diseases, such as myocardial infarction [19; 37].  For over 60 years, numerous 
case reports and case series indicated that people with schizophrenia have reduced pain sensitivity 
[16] leaving clinicians perplexed when this population appears not to report pain in the face of 
ordinarily painful comorbidities.  For instance, Lieberman [38] established that over 85% of patients 
with psychosis experiencing myocardial infarction did not report experiencing pain.  This finding has 
been replicated numerous times since.  For example, Hussar [27; 28] found that 60% of people with 
schizophrenia that died from a coronary heart disease reported no pain.  This phenomenon persists 
to the present day and despite the high rates of cardiometabolic abnormalities in people with 
schizophrenia [52], it is noteworthy that there is a negligible increase of patients with schizophrenia 
presenting to hospitals with heart disease compared to the general population [35], which may 
contribute to the established increased premature mortality in people with schizophrenia [12; 41].   
Consistent with the possibility of reduced pain sensitivity in schizophrenia, Stubbs et al [49] found 
that the prevalence of pain in those with schizophrenia was comparable to that of controls in a 
meta-analysis of over 5 million people (relative risk (RR)=0.99, 95% CI=0.83–1.19), despite the fact 
that schizophrenia is linked to a greater number of conditions ordinarily associated with pain [11; 12; 
48]. Whilst the review of Stubbs et al [49] was helpful, the reliance on pain data from self-report and 
lack of pain severity measures in most studies might have introduced bias and noise. For example, 
cognitive deficits may impede the ability of people with schizophrenia to recognise and 
communicate the presence of pain [7].  In addition, the investigation of the prevalence of pain in 
schizophrenia patients is further complicated by the fact that antipsychotic medications have 
analgesic properties [45].  Nevertheless, understanding if people with schizophrenia have reduced 
pain sensitivity has important implications and poses a central clinical challenge, since a  patient’s  
inability to recognise pain may lead to increased risk for morbidity and ultimately mortality [29].  
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Experimental pain testing methods circumvent some of the concerns associated with data obtained 
from a purely clinical setting. Firstly, they allow for precise controllability of the noxious stimulus 
ensuring equivalent stimulation across groups. Secondly, they facilitate the recording of 'objective' 
non-verbal measures of pain, typically autonomic stress indices such as heart rate and pupillary 
dilation and thus offer a superior method for investigating algesia and hypoalgesia in people with 
schizophrenia. When considering experimental studies, it is important to establish the methods of 
pain induction (e.g., thermal, mechanical, chemical) and measurement including (1) pain threshold, 
(2) pain tolerance, (3) sensory threshold, (4) physiological responses to painful stimuli, and (5) 
ratings of pain intensity/unpleasantness [23].  It remains unclear to what extent people with 
schizophrenia have reduced pain sensitivity in each of these measures of pain.   
Only one previous review [43], with a last search date of almost a decade ago, investigated 
differences in experimental pain responses in people with schizophrenia versus controls.  The 
authors aggregated all different types of pain measures together in a composite analysis and found 
that people with schizophrenia appeared to exhibit hypoalgesia.  Whilst this review advanced the 
field, the authors included only 11 studies and 497 participants in a composite analysis in which they 
pooled any pain measures per study. Moreover, the authors were only able to pool data from 3 and 
6 studies to investigate sensory threshold and pain threshold, respectively. Thus, only 2 of the 5 
dimensions of pain sensitivity in people with schizophrenia were explored in that prior review.  
Other important facets of pain sensitivity, such as pain tolerance, physiological responses to painful 
stimuli, and ratings of pain intensity/unpleasantness were not explored, but may have important 
implications.  In addition, pooling data on physiological responses to pain may offer a unique insight 
that circumvents concerns regarding cognitive and communication deficits when recognising and 
reporting pain in schizophrenia [7].   
Given the importance of pain sensitivity in schizophrenia and lack of a comprehensive analysis of the 
available data of experimental pain studies, we aimed to investigate if people with schizophrenia-
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spectrum disorders have reduced pain sensitivity under experimental pain conditions, assessing the 
different dimensions of pain. Based on the available data, we hypothesized that people with 
schizophrenia would exhibit decreased pain sensitivity in the form of reduced physiological response 
and ratings of pain and increased pain tolerance and threshold. We further hypothesized that these 
findings would be accentuated in antipsychotic-free patients. 
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Method 
This systematic review was conducted in accordance with the MOOSE guidelines [47] and in line with 
the PRISMA statement [40], following a predetermined, but unpublished protocol.   
 
Inclusion criteria 
Included in this meta-analysis were studies that: (1) Included adult participants with schizophrenia-
spectrum disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, as well as 
samples with >50% non-affective psychotic), diagnosed according to established criteria (e.g., DSM-
IV, [2] or ICD-10, [42]); (2)  Investigated any type of experimentally induced pain reporting data on 
(a) pain threshold, (b) pain tolerance, (c) sensory threshold, (d) physiological responses to noxious 
stimuli, or (e) ratings of pain intensity/ unpleasantness; (3) reports comparative data in a healthy 
control group; and  (4) were published in an international peer-reviewed journal or conference 
abstract.   
 
Information sources and searches 
Three independent reviewers (BS, TT, SA) searched Academic Search Premier, MEDLINE, Psychology 
and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed without 
language restrictions from database inception until April 15th, 2015, using the key words 
‘schizophrenia’  or  ‘schiz*’  or  ‘psychosis’  or  ‘psychoses’  or  ‘psychotic’  and  ‘pain*’ or  ‘nociception’  or  
‘cold’  or   ‘heat’  or   ‘electrical’  or   ‘thermal’  or   ‘reflex’   ‘hypoalgesia’.  In addition, reference lists of all 
eligible articles and reviews of pain in schizophrenia were screened to identify additional studies.  
We contacted corresponding/first authors up to 3 times over a month to clarify study eligibility 
and/or acquire additional data.    
 
Study selection 
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After removal of duplicates, two independent reviewers screened the titles and abstracts of all 
potentially eligible articles. Two authors applied the eligibility criteria, and a list of full text articles 
was developed through consensus. Two authors (BS, TT) considered the full texts of included articles 
and a final list of included articles was reached through consensus.   
 
Outcomes: 
Primary outcome was a composite of selected measures of pain sensitivity that was derived by 
pooling the means and SDs of the following 3 individual parameters: (1) pain threshold, (2) pain 
tolerance, (3) sensory threshold. These 3 parameters were selected, as threshold and tolerance are 
typically correlated (e.g. [51]). Secondary outcomes were these three parameters by themselves plus 
two additional individual outcomes, namely (4) physiological responses to painful stimuli, and (5) 
ratings of pain intensity/unpleasantness.    
 
Data Extraction 
Two authors (TT, BS) extracted data using a data extraction form, including: study design, 
geographical location, details of schizophrenia participants (mean age, % males, diagnosis and 
utilized criteria, first episode, duration of illness body mass index, psychopathology scores, 
psychopharmacologic treatment, including % on antipsychotics (including type), antidepressants and 
mood stabilisers), and type and method of experimental pain measure assessment.  We also 
abstracted details regarding the control group, including mean age, sex and body mass index.  
Finally, we extracted data on the mean and standard deviation (SD) for each experimental pain 
measurement.   
When studies reported data from the same sample at different time points, we used the most recent 
data and/or the largest data set.  From duplicate studies reporting experimental pain data in 
participants before and after antipsychotic medication treatment, we included the antipsychotic-
free data for the overall pooled analyses, but also used the data in antipsychotic-treated patients in 
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subgroup analyses.  Studies that employed sensory decision theory to determine pain threshold 
reported two measures: response criterion and d' (sensory discrimination). Response criterion was 
abstracted as the data of interest, as this measure is the most closely related to pain threshold used 
in the other included studies, which assessed pain threshold through verbal declaration [23].   
 
Meta-analysis 
Due to the anticipated heterogeneity, we adopted the random effects meta-analysis and calculated 
Hedges’s g 95% confidence intervals (CIs) as the effect size measure (ES) comparing pain sensitivity 
between participants with schizophrenia-spectrum  disorders  (henceforward  called  “schizophrenia”)  
and controls using Comprehensive Meta-Analysis (CMA, Version 3).  In line with a previous meta-
analysis [43], we examined the funnel plot of the composite outcome searching for extreme outliers 
and removed from the database and all analyses one extreme publication bias outlier [39].  Across 
the resultant sample of 17 studies, we first conducted a composite analysis pooling aggregated pain 
measure data on pain threshold, pain tolerance and sensory threshold together from all studies to 
establish an overall difference in pain sensitivity.  We further pooled data separately for: (1) pain 
threshold, (2) pain tolerance, (3) sensory threshold, (4) physiological responses to painful stimuli, 
and (5) ratings of pain intensity/unpleasantness. We conducted subgroup analyses for the composite 
and each individual pain measure in patients who were antipsychotic-free or antipsychotic-treated 
at the time of experimental pain induction and assessment. Additional exploratory analyses 
compared the composite score in the same population off and on antipsychotics in those studies 
were patients were reassessed after antipsychotics were started. Heterogeneity was assessed with 
the I2 statistic for each analysis [26].  Furthermore, we conducted meta-regression analysis with CMA 
when data were available in at least 3 studies, assessing the moderating effects of mean age, % 
females in both cohorts separately, and duration of illness and summary scores of psychiatric 
symptoms (measured with a standardised scale, e.g., PANSS [32]) in the schizophrenia cohort.  
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Publication bias was assessed with a visual inspection of funnel plots and with the Begg-Mazumdar 
Kendall's tau [4]and Egger bias test [17].   
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Results 
Study selection, Study and participant characteristics 
The initial search yielded 2532 hits. After removal of duplicates, 1989 abstracts and titles were 
screened.  A further 20 abstracts were screened following a review of references from previous 
systematic reviews [7; 43].  At the full text review stage, 28 articles were considered and 11 were 
subsequently excluded (see Figure 1 for search results).  Overall, 18 unique samples from 17 
publications were included in the meta-analysis [1; 3; 5; 6; 8; 10; 13-15; 21; 22; 24; 30; 31; 34; 44; 
46].  One publication [15] contained two unique studies with different samples and is henceforth 
considered as two unique studies.  Full details of the included studies are summarised in Table 1.   
Figure 1 
Table 1 
Across the 18 unique samples there were 387 participants with schizophrenia (mean age=30.7±6.9 
years, females=31.9% (range=0%-70%), illness duration=7.0±5.7 (range=1.0-17.1).  Altogether, 483 
control participants were included (mean age=29.5±7.4 years, females=31.0% (range=0%-70%).  
Eight samples across seven studies were conducted in North America [8; 10; 15; 22; 31; 44], six 
studies in Europe [1; 3; 6; 21; 24; 30] and four were conducted in in other parts of the world [5; 13; 
34; 46] (Table 1).  
Twelve studies provided pain data for participants taking antipsychotic medication including 282 
participants with schizophrenia (mean age 33.4 years±8.2 years, 38.9% female (range 17-70%) and 
310 controls (31.7 years±7.9, 40.5% female (range 23-80%).  Eight studies provided data for 140 
individuals with schizophrenia who were antipsychotic free (31.8±4.4 years, 32% female (range 0-
70%) and 215 controls (30.7±6.0 years, 29.5% female (range 0-70%).  Ten studies induced pain with 
thermal methods [1; 3; 6; 13-15; 22; 30; 31; 44] and five used electrical inducement [5; 8; 10; 24; 34] 
whilst two induced pain mechanically [21; 46]. Details of each study, including medication data 
(where available), pain modalities and assessed parameters are summarised in table 1. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
Table 2 
Meta-analysis investigating pain sensitivity in people with psychosis 
In the composite analysis of 17 unique samples, people with schizophrenia had reduced pain 
sensitivity versus controls (ES=0.493, 95% CI=0.145-0.839, p=0.005; I2=81%, n=847; Table 2, figure 2).  
There was no evidence of publication bias (Begg=0.08, p=0.60, Egger test=4.56, p=0.18).   
Figure 2 here 
In a subgroup analysis, results were confirmed in antipsychotic-free patients (ES=0.599, 95% 
CI=0.291-0.907, p<0.0001, I2=41%, studies=8, n=371 table 2, figure 3a), without evidence of 
publication bias (Egger test =3.6, p=0.26, Begg=0.25, p=0.36).   
In contrast, antipsychotic-treated patients did not differ from controls regarding pain sensitivity 
(ES=0.428, 95%=-0.059-0.915, p=0.08, I2=86%, studies=11, n=542, figure 3b; Begg =-0.018, p=1.0, 
Egger test =4.4, p=0.38, table 2, figure 3b). 
In exploratory analyses of composite pain measures before and 5 weeks after antipsychotic initiation 
in the same patients from two studies (n=35), there was a significant reduction in pain sensitivity 
after antipsychotics were started (ES=-0.279, 95% CI -0.483 to -0.075, p=0.007, I2=0%). 
Figure 3 a and b here 
Meta-regression of predictors of pain sensitivity 
In meta-regression analyses of pain sensitivity across all studies, mean age, percentage of females, 
illness duration and psychopathology scores did not moderate significantly pain sensitivity (p>0.05, 
data not shown). 
 
Meta-analysis investigating differences in different pain measures/modalities 
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Pain threshold 
Across 9 studies (n=439), people with schizophrenia had significantly higher pain threshold than 
controls (ES=0.696, 95% CI 0.407-0.986, p<0.001, I2=51%, Begg=0.35, p=0.26, Egger=3.7, p=0.25, 
table 2).  In sub-group analyses, pain threshold was higher than in controls in both antipsychotic-free 
(ES=0.753, 95% CI 0.305-1.202, p<0.001, I2=61%, studies=5, n=252) and antipsychotic-treated 
participants (ES=0.706, 95% CI 0.354-1.05, P<0.001, I2=49%, studies=5, n=195, table 2).   
Meta-regression of pain threshold 
Only greater total psychiatric symptoms severity was a significant moderator of pain threshold 
(β=0.0156, 95%CI=0.0025-0.0286, z=2.34, p=0.019, R2=1.0, studies=4, n=155), explaining the entire 
between-study variance. 
Pain tolerance 
Across 7 studies (n=366) pain tolerance did not appear reduced in people with schizophrenia 
(ES=0.393, 95%CI=-0.048-0.836, p=0.08, I2=74%, table 2).  However, the funnel plot identified one 
striking outlier [22] for pain tolerance . After removal of this study, schizophrenia patients had 
significantly greater pain tolerance than controls (ES=0.566, 95% CI=0.235-0.897, p=0.0001, I2=49%, 
studies=6, Egger=2.26, p=-0.58, Begg=0.13, p=0.70, studies=6, n=330).  Subgroup analyses with the 
outlier removed established similar results in antipsychotic-free (ES=0.342, 95%CI=0.03-0.645, 
p=0.02, I2=41%, studies=4, n=190) and antipsychotic-treated participants (ES=0.745, 95%CI=0.461-
1.02, p<0.0001, I2=0%, studies=4, n=211) (table 2).   
Meta-regression of pain tolerance 
Only   a   higher  mean   age   of   schizophrenia   participants   significantly  moderated  pain   tolerance   (β=-
0.058, 95% CI -0.1to-0.0161, z=-2.71, p=0.006, R2=1.0, studies=6, n=330).   
Sensory threshold 
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Across 5 studies (n=294), people with schizophrenia had a higher sensory threshold than controls 
(ES=1.16, 95%CI=0.505-1.727, p<0.0001, I2=77%, Begg=0.33, p=0.46, Egger= -26.3, p=0.43, table 2).  
Similar results were found in antipsychotic-free participants (ES=0.807 (95% CI 0.168 to 1.446, 
p=0.01, I2=71%, studies=3, n=165), whereas not data were available in antipsychotic-treated 
individuals (table 2).   
Meta regression of sensory threshold 
No significant moderators were identified. 
Physiological responses to pain 
Across 4 studies (n=190), the physiological response to pain was significantly reduced in people with 
schizophrenia compared to controls (ES=0.465, 95% CI=0.131-0.783, p=0.006, I2=1%, Begg=0, p=1, 
Egger=5.1, p=0.73, table 2).  Similar results were found in antipsychotic-free individuals (ES=0.505, 
95%CI=0.072-0.941, p=0.02, I2=28%, studies=3, n=145), whereas no data were available in 
antipsychotic-treated individuals (table 2).   
Pain rating of intensity/ unpleasantness  
Across 3 studies (n=95), all in antipsychotic-free patients, ratings of pain unpleasantness were lower 
compared to controls (ES=0.547, 95% CI=0.146-0.949, p=0.008, I2=0%, Begg=0.33, p=0.60, 
Egger=0.69, p=0.95, table 2).   
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Discussion 
Results of the largest and most comprehensive meta-analysis of experimental pain studies in 
schizophrenia-spectrum disorder patients indicate that 1) across all studies, using a composite 
outcome, patients had elevated pain threshold/pain tolerance/sensory threshold versus controls; 2) 
results were similar in antipsychotic-free individuals, but showed only trend level significance in 
antipsychotic-treated individuals; 3) in 2 longitudinal studies, antipsychotic initiation significantly 
decreased pain sensitivity; 4) pooling results across individual outcomes, patients had increased pain 
tolerance, sensory threshold and pain threshold, yet reduced physiological response to painful 
stimuli and ratings of pain intensity/unpleasantness; 5) after removal of one marked outlier, findings 
regarding individual outcomes were similarly significant in antipsychotic-free and antipsychotic-
treated individuals; and 6) in meta-regression analyses, greater psychiatric symptoms and younger 
patient age moderated increased pain tolerance/threshold. 
Our results are consistent with a more preliminary prior meta-analysis [43]. In this paper, the 
authors had reported hypoalgesia to experimentally induced pain that was independent of 
antipsychotic treatment using a composite analysis in which any pain measure, albeit very divergent 
parameters were pooled together. However, that prior quantitative review included only 11 studies 
and 497 participants compared to our meta-analysis in which we were able to analyse data from 18 
unique samples including 870 participants. Furthermore, the prior meta-analysis was only able to 
pool data individually for sensory threshold and pain threshold, i.e., for only 2 of the 5 specific pain 
sensitivity dimensions that we were able to analyse separately, which enabled us to confirm and 
extend the results of decreased pain sensitivity across different pain measures and both in samples 
on and off antipsychotics.   
 
The exact reasons for the observed deficits in pain sensitivity in people with schizophrenia are 
complex, likely multifactorial [7; 29] and may, given the heterogeneous nature of schizophrenia, vary 
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from patient to patient and over time.  Importantly, however, the finding of a blunted physiological 
response to noxious stimuli confirms for the first time that individuals with schizophrenia genuinely 
appear to exhibit hypoalgesia rather than simply failing to report pain. Thus, hypoalgesia appears to 
be an endophenotype of schizophrenia, which could be explained by several neurobiological 
processes. First, impaired prefrontal and medial temporal functioning in schizophrenia [33] may 
result in a reduced pain experience.  Specifically, prefrontal cortex hypofunctioning may result in 
alterations in the motivational affective processing of pain [18] which may translate into difficulties 
in recognising and expressing pain [7; 53].  Second, impairments within the mediodorsal thalamus 
and hippocamapus (both central parts of the medial pain system) may play a role in modifying 
affective and cognitive evaluative processes of pain among people with schizophrenia [20], 
translating into decreased pain experience.  Third, alterations in the cortical dopamine system and 
higher vulnerability of COMT Met allele may account for reduced pain sensitivity in people with 
schizophrenia [29]. Fourth, there may also be decreased primary sensory-discriminative pain 
processing functioning. For example, one study included in our meta-analysis [13] utilised functional 
magnetic resonance imaging to explore blood oxygen level dependent changes (BOLD) in response 
to experimentally induced pain in 12 antipsychotic-free people with schizophrenia. The authors 
found a greater BOLD response in patients in the primary sensory-discriminative pain processing 
region (S1) compared to controls, and noticed reduced activity in the posterior cingulate cortex, 
insula and brain stem, suggesting abnormal central processing during painful stimuli.  Taken 
together, these findings suggest decreased pain sensitivity as a potential endophenotype of 
schizophrenia, which may be relevant to enhance diagnostic precision in general, or predictive 
validity during the ultra-high risk syndrome for psychosis [9]. Furthermore, studies should investigate 
if symptomatic response to antipsychotic treatment is related to a normalization of pain sensitivity 
and/or if baseline values could be predictive of future symptomatic response. 
Moreover, due to increased sensory and pain thresholds as well as greater pain tolerance, 
individuals with schizophrenia may not register potentially harmful stimuli that are related to often 
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co-occurring physical comorbidities until they becomes more advanced, which could possibly 
contribute to the low help-seeking among people with schizophrenia [11; 12], since pain is the 
primary reason that people seek medical help,[25] .  Given that people with schizophrenia already 
experience multiple barriers in accessing medical care [11; 12] these results are concerning.  
Antipsychotics are known to be analgesic [45], which was reflected by our exploratory finding of two 
longitudinal studies [13; 14; 30], in which antipsychotic initiation further reduced pain sensitivity. 
Nevertheless, hypoalesia was clearly apparent in antipsychotic free individuals, indicating that 
reduced pain sensitivity appears to be a trait marker that is independent of antipsychotic effects.  
Finally, for the first time, we investigated moderators that may explain the reduced pain sensitivity 
in people with schizophrenia.  In meta-regression analyses, greater psychiatric symptoms and 
younger patient age moderated increased pain tolerance/threshold.  Curiously, the inverse age 
effect is in contrast to increases in pain threshold in older adults in the general population [36].   
Whilst this is the most comprehensive meta-analysis of experimental pain research in participants 
with schizophrenia to date, a number of limitations need to be considered.  First, although we 
increased the number of studies and participants compared to the previous meta-analysis by 39% 
and 43%, this meta-analysis still only contains a modest number of studies and participants, 
especially when considering individual pain parameters.  Second, there were insufficient data to 
investigate pain sensitivity among people with first episode psychosis. Third, there were insufficient 
details within the included studies to determine if the antipsychotic-free participants were actually 
antipsychotic-naïve or (more likely) had stopped prior treatment for some (unknown) duration. 
Moreover, other psychotropic medications may also have influences pain sensitivity, but data were 
too sparse to examine this further.  Fourth, too few studies examined pain sensitivity in patients 
before and after antipsychotic treatment, and none examined the relationship between changes in 
pain sensitivity and psychopathology over time. Finally, some results were heterogeneous. However, 
we were able to explain this heterogeneity in a number of our meta-regression analyses.   
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Future experimental research is required to better understand the interaction between different 
dimensions of schizophrenia and decreased pain sensitivity, such as various aspects of 
psychopathology, including negative symptoms and cognition, and medication effects (both before 
and after treatment and in those truly antipsychotic-naïve).  Meta-regression analyses suggested 
that greater global psychiatric symptom severity contribute to reduced pain sensitivity, but it was 
not possible to investigate the influence of negative symptoms or cognitive deficits within our 
analyses due to paucity of data.  Future work is required to understand these potential interactions.  
Research investigating physiological responses to painful stimuli should be increased, given that 
decreased pain sensitivity may be an endophenotype of schizophrenia and related disorders and 
that decreased identification and reporting of pain may be directly related to the low help-seeking 
and insufficient treatment of medical comorbidities in patients with schizophrenia [11; 12].  Finally, 
research is needed that investigates methods to assist clinicians to identify people with 
schizophrenia with painful comorbidities and ultimately seeks to demonstrate how this increased 
detection of pain may improve patient care, morbidity, quality of life and mortality.   
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Figure 1. PRISMA 2009 flow diagram for search strategy 
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Figure 2. Pooled Analysis of All Studies Comparing Experimentally Induced Pain Sensitivity in 
Schizophrenia-Spectrum Patients Versus Controls 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
 Kudoh et al 2000 2.850 2.069 3.631 0.000
Boettger et al 2013 1.177 0.571 1.784 0.000
Blumensohn et al 2002 1.155 0.585 1.725 0.000
de la Fuente-Sandoval et al 2010 1.115 0.296 1.934 0.008
Davis et al 1981 0.930 0.237 1.622 0.009
Jochum et al 2006. 0.666 0.082 1.250 0.025
Atik et al 2007 0.532 0.074 0.990 0.023
Guieu et al 1994 0.511 -0.343 1.365 0.241
Song and Yi 2000 0.482 -0.090 1.054 0.098
Kane et al 1971 0.474 -0.143 1.091 0.132
Potvin et al 2008 0.160 -0.362 0.682 0.548
Collins and Stone 1966 0.082 -0.444 0.607 0.760
Dworkin et al 1993b 0.080 -0.554 0.713 0.805
Albus et al 1982 0.078 -0.533 0.689 0.802
Girard et al 2001 -0.291 -0.757 0.175 0.221
Dworkin et al 1993a -0.472 -1.121 0.177 0.154
Goldman et al 2007 -0.837 -1.541 -0.132 0.020
0.492 0.145 0.839 0.005
-4.00 -2.00 0.00 2.00 4.00
Increased Pain Sensitivity Decreased Pain Sensitivity
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Figure 3a. Differences in Experimentally Induced Pain Sensitivity in Antipsychotic-Free Patients 
Compared to Controls 
 
  
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
Boettger et al 2013 1.177 0.571 1.784 0.000
de la Fuente-Sandoval et al 2010 1.115 0.296 1.934 0.008
Davis et al 1981 0.930 0.237 1.622 0.009
Jochum et al 2006. 0.666 0.082 1.250 0.025
Guieu et al 1994 0.511 -0.343 1.365 0.241
Kane et al 1971 0.474 -0.143 1.091 0.132
Collins and Stone 1966 0.082 -0.444 0.607 0.760
Albus et al 1982 0.078 -0.533 0.689 0.802
0.599 0.291 0.907 0.000
-4.00 -2.00 0.00 2.00 4.00
Increased Pain Sensitivity Decreased Pain Sensitivity
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Figure 3b. Differences in Experimentally Induced Pain Sensitivity in Patients Taking Antipsychotics 
Compared to Controls 
 
 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
 Kudoh et al 2000 2.850 2.069 3.631 0.000
Blumensohn et al 2002 1.155 0.585 1.725 0.000
de la Fuente-Sandoval et al 2012 0.777 -0.012 1.565 0.054
Atik et al 2007 0.532 0.074 0.990 0.023
Song and Yi 2000 0.482 -0.090 1.054 0.098
Jochum et al 2006 0.461 -0.115 1.037 0.117
Potvin et al 2008 0.160 -0.362 0.682 0.548
Dworkin et al 1993b 0.080 -0.554 0.713 0.805
Girard et al 2001 -0.291 -0.757 0.175 0.221
Dworkin et al 1993a -0.472 -1.121 0.177 0.154
Goldman et al 2007 -0.837 -1.541 -0.132 0.020
0.428 -0.059 0.915 0.085
-4.00 -2.00 0.00 2.00 4.00
Increased Pain Sensitivity Decreased Pain Sensitivity
Table 1 summary of included studies 
Author Location & 
Setting 
Schizophrenia participants Antipsychotic 
Treatment 
Control 
participants 
Pain 
modality 
Pain measure used 
Antipsychotic-Treated Individuals 
Atik et al 2007  Turkey, 
outpatients 
N=27, schizophrenia, 51.9% female, 
age=31.7 years, 10.7 years illness 
duration. , 25% taking antidepressants 
BPRS= 22.1 
83% taking various 
antipsychotics 
N=59, 45.8% 
female, age=32.0 
years,  
Thermal Pain threshold 
Pain tolerance 
Pain intensity 
 
Blumensohn et 
al 2002 
Israel, 
inpatients 
N=25, schizophrenia acute, 48% 
female, age=19.1 years.  
100% taking 
various 
antipsychotics 
N=29, 48.3% 
female, age=19.9 
years 
Electrical Pain threshold 
Pain tolerance 
Sensory threshold 
Dworkin et al. 
1993 (A) 
US, inpatients N=17, 15 schizophrenia, 2 
schizoaffective disorder, age=35 years. 
100% taking 
various 
antipsychotics 
N=19, age=30.4 
years,  
Thermal Sensory discrimination 
Response criterion 
Dworkin et al. 
1993 (B) 
US, inpatients N=13, 8 schizophrenia, 3 
schizoaffective disorder, 2 schizotypal 
disorder, age=26.6 years 
Details not stated 
but treated as 
medicated 
N=32, age=23.1 
years 
Thermal Sensory discrimination 
Response criterion 
Goldman et al 
2007 
US, mixed 
setting 
N=24, 20 schizophrenia, 4 
schizoaffective disorder, 33% female, 
age=41.6 years,  17.1 years illness 
duration, PANSS total 59.55 
100% taking 
haloperidol or 
olanzapine 
N=12, 42% female, 
age=38.3 years,  
Thermal Pain intensity 
Pain tolerance 
Blood pressure change 
Jochum et al 
2006*  
 
Germany, 
inpatients 
N=23, schizophrenia, 70% female, 
age=34.4 years, 8.6 years illness 
duration, SAPS 47.4, SANS 32.5,  
100% taking 
various 
antipsychotics 
N=23, 70% female, 
37.8 years 
Thermal Pain threshold 
Pain tolerance 
Sensory threshold 
Kudoh et al 
2000 
Japan, 
unclear 
setting 
N=50 schizophrenia, age=46.3 years. 100% taking 
various 
antipsychotics 
N=25, age=45.3 
years 
Electrical Sensory threshold 
Pain intensity 
Potvin et al 
2008 
Canada, 
mixed (91% 
outpatients) 
N= 23,18 schizophrenia, 5 
schizoaffective disorder, 22% female, 
age=36.9 years, 5.2 years illness 
duration  
100% taking 
various 
antipsychotics 
N=29, 28% female, 
age=32.6 years, 
Thermal Pain intensity 
 
de la Fuente-
Sandoval et al 
2010*  
Mexico, 
mixed setting 
N=12, schizophrenia, 17% female, 
age=23.6 years, 1.4 years illness 
duration, PANSS total 86.7.  
100% taking 
various 
antipsychotics* 
N=13, 23% female, 
age=26.1 years 
Thermal Pain tolerance 
Pain intensity 
Pain unpleasantness 
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Table 1 summary of included studies 
Author Location & 
Setting 
Schizophrenia participants Antipsychotic 
Treatment 
Control 
participants 
Pain 
modality 
Pain measure used 
Girard et al 
2011 
France, 
inpatients 
N=35, 37% female, age 41.9 whole 
sample, 11.3 years illness duration, 
SAPS 36.3, ,  
? all taking various 
antipsychotics 
N=35, no data on 
gender or age  
Mechanical Pain intensity 
Mechanical Pressure Time 
Lévesque  et  al  
2012 
Canada, 
outpatients 
N=12, schizophrenia, 33% female, 31.3 
years, .6 years illness duration, PANSS 
total 64.7,  
100% taking 
various 
antipsychotics 
N=11, age=31.5 
years, 27% female 
Electrical Pain threshold 
Withdrawal reflex 
Pain intensity 
Song and Yi 
2000 
Asia, unclear 
setting 
N=21; schizophrenia, no data on 
gender or age 
All taking 
antipsychotics 
N=23, no data on 
gender or age 
Mechanical Pain threshold 
Subtotal 
Antipsychotic-
Treated 
Studies=12; 
Region: 
USA=3, 
Other=3, 
Canada=2, 
Europe=2, 
Asia=2; 
Setting: 
Outpatient=5, 
Inpatients2=, 
Mixed=3, 
Unclear=2 
N=282, age=33.4 years±8.2 years, 
females=38.9% (range=17-70%).   
Antipsychotic-
Treated=11; 
Unclear=1 
N=310, age=31.7 
years±7.9, 40.5% 
female (range 23-
80%) 
Thermal=7; 
Electrical=3; 
Mechanical=2  
Pain intensity=7; 
Pain threshold=5;  
Pain tolerance=5; 
Sensory threshold=3; 
Physiological response=2; 
Sensory discrimination=1; 
Response criterion=1 
 
Antipsychotic-Free Individuals 
Collins and 
Stone 1966  
US, inpatients N=18, schizophrenia, 0% female, 
age=32.8 years, 0% taking 
antidepressant or mood stabilisers 
Antipsychotic-free N=56, 0% female, 
age=27.1 years,  
Electrical Pain threshold 
Pain tolerance 
Sensory threshold 
Davis et al 
1981 
US, inpatients N=17, schizophrenia, 33% female, 
age=26 years, 0% taking 
antidepressant or mood stabilisers 
Antipsychotic-free N 17, matched for 
age and gender, 
but data not given 
Electrical Pain threshold 
Response criterion 
EEG 
Guieu et al 
1994  
France, 
unclear 
setting  
N=10 , schizophrenia, 60% female, 
age=35.4 years, 0% taking 
antidepressant and mood stabiliser, 
6.1 years illness duration 
Antipsychotic-free N=10, 40% female, 
age=31.6 years,  
Electrical Pain threshold 
Table 1 summary of included studies 
Author Location & 
Setting 
Schizophrenia participants Antipsychotic 
Treatment 
Control 
participants 
Pain 
modality 
Pain measure used 
Jochum et al 
2006*  
 
 
Germany, 
inpatients 
N=23, schizophrenia, 70% female, 
age=34.4 years, 8.6 years illness 
duration, SAPS 47.4, SANS 32.5,  
Antipsychotic-free 
(and retested with 
100% taking 
various 
antipsychotics*) 
N=23, 70% female, 
37.8 years 
Thermal Pain threshold 
Pain tolerance 
Sensory threshold 
Kane et al 
1971 
Canada, 
inpatients 
N=30, schizophrenia , 0% female, 
age=34.4 years,3 years illness duration  
Antipsychotic-free N=15, 0% female, 
age=21.6 years,  
Thermal Pain threshold 
Pain tolerance 
Sensory threshold 
Albus et al 
1982 
Germany, 
inpatients 
N=12 schizophrenia, 34 years  Antipsychotic-free N=63, age=37 
years,  
Thermal Heart rate change 
EEG 
Boettger et al 
2013 
Germany, 
inpatients 
N=18, schizophrenia, 44% female, 
age=34 years, PANSS total 86  
Antipsychotic-free N=18, 44% female, 
age=34 years,  
Thermal Pain threshold 
Pain intensity 
Pain unpleasantness 
de la Fuente-
Sandoval et al 
2010 * 
Mexico, 
mixed setting 
N=12, schizophrenia, 17% female, 
age=23.6 years, 1.4 years illness 
duration, PANSS total 86.7.  
Antipsychotic-free 
(and retested with 
100% taking 
various 
antipsychotics*) 
N=13, 23% female, 
age=26.1 years 
Thermal Pain tolerance 
Pain intensity 
Pain unpleasantness 
Subtotal 
Antipsychotic 
free 
Studies=8; 
Region: 
Europe=4, 
USA=2, 
Canada=1, 
Other=1; 
Setting: 
Inpatients=6, 
Outpatient=1, 
Unclear=1 
N=140 schizophrenia, age=31.8±4.4 
years, females=32% (range=0-70%) 
Antipsychotic-
free=8 
(and retested with 
100% taking 
various 
antipsychotics*=2) 
N=215, age-
30.7±6.0 years, 
29.5% female 
(range 0-70%) 
Thermal=5; 
Electrical=3  
Pain threshold=6;  
Pain tolerance=4; 
Sensory threshold=3; 
Pain intensity=2; 
Pain unpleasantness=2; 
Physiological response=2; 
EEG=2 
Response criterion=1 
 
TOTAL Studies=18;  
Region: 
USA=5, 
N=387 participants with schizophrenia 
spectrum, mean age=30.7±6.9 years, 
females=31.9% (range=0%-70%), 
Antipsychotic-
Treated=11;  
Antipsychotic-
N=483 control 
participants, mean 
age=29.5±7.4 
Thermal=10; 
Electrical=6; 
Mechanical=2  
Pain threshold=10;  
Pain intensity=8; 
Pain tolerance=7; 
Table 1 summary of included studies 
Author Location & 
Setting 
Schizophrenia participants Antipsychotic 
Treatment 
Control 
participants 
Pain 
modality 
Pain measure used 
Europe=5, 
Canada=3, 
Other=3, 
Asia=2; 
Setting: 
Outpatient=6 
Inpatients=7, 
Mixed=2, 
Unclear=2 
illness duration=7.0±5.7 (range=1.0-
17.1).  
free=8 (and 
retested on 
antipsychotic=2); 
Unclear=1 
years, 
females=31.0% 
(range=0%-70%) 
Sensory threshold=5; 
Physiological response=4; 
Pain unpleasantness=1; 
EEG=2 
Response criterion=2 
Sensory discrimination=1 
Key: BPRS= Brief Psychiatric Rating Scale, EEG= electroencephalography, PANSS= Positive and Negative Syndrome Scale, SANS= Scale for the Assessment of 
Negative Symptoms, SAPS= Scale for the Assessment of Positive Symptoms, US= United States, *=authors published two papers on same participants, one 
in antipsychotic-free individuals and one in people taking antipsychotic medications.  Dworking et al 1993 A and B are two unique studies contained in one 
publication.   
 
Table 2 Summary of pain sensitivity results within meta-analysis 
Pain Measure Overall hedges 
g (95% CI) 
P value 
Number studies 
(N) and number 
participants (n) 
Hedges g AP free 
(95% CI) 
P value 
Number studies 
(N) and number 
participants (n) 
Hedges g 
Medicated (95% 
CI), P value 
Number studies 
(N) and number 
participants (n) 
Composite analysis 0.493 (95% CI 
0.145-0.839) 
p=0.005 
N=17 
n=847 
0.599 (95% CI 
0.291 - 0.907) 
p<0.0001 
N=8 
n=371 
0.428 (95%0.059 - 
0.915) 
p=0.08 
N=11 
n= 542 
Pain threshold  0.696 (95% CI 
0.407-0.986) 
p<0.001 
N=9 
n=439 
0.753 (95% CI 
0.305-1.202) 
p<0.001 
N=5 
n=252 
0.706 (95% CI 
0.354-1.05) 
P<0.001 
N=5 
n=195 
Pain tolerance 0.393, (95%CI=-
0.048-0.836), 
p=0.08 
N=7 
n=366 
0.342 (95% CI 0.03-
0.645) p=0.02 
N=4 
n=190 
0.453 (95% CI -
0.135 – 1.04) 
P=0.1 
N=5 
n=237 
Pain tolerance with 
Outlier Removed* 
0.566 (95% CI 
0.235-0.897) 
p=0.0001 
N=6 
n=330 
0.342 (95% CI 0.03-
0.645) p=0.02 
N=4 
n=190 
0.745 (95% CI 
0.461-1.02) 
p<0.0001 
N=4 
n=211 
Sensory Threshold 1.16 (95% CI 
0.505-1.727) 
p<0.0001 
N=5 
n=294 
0.807 (95% CI 
0.168-1.446) 
p=0.01 
N=3 
n=165 
N/A N/A 
Pain ratings of 
unpleasantness 
0.547 (95% CI 
0.146-0.949) 
p=0.008 
N=3 
n=95 
0.547 (95% CI 
0.146-0.949) 
p=0.008 
N=3 
n=95 
N/A N/A 
Physiological 
response to painful 
stimuli 
0.465 (95% CI 
0.131-0.783) 
P=0.006 
N=4 
n=190 
0.505 (95% CI 
0.072-0.941) 
P=0.02 
N=3 
n=145 
N/A N/A 
Pain sensitivity 
changes before and 
after antipsychotic 
medication 
-0.279 (95% CI -
0.483 - -0.075) 
P=0.007 
N=2 
n=35 
    
Key: g=hedges g, N=number of studies, n=number of participants, CI=confidence interval, *=outlier remover details and reason in manuscript text, N/A= not 
available for meta-analysis 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  5-7 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
6-7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
8 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
8 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
8-9 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
8-9 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
8-9 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
8-9 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8-9 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
9-10 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  10-11 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
10-11 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
10-11 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
10-11 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
12 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
12-13 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  12-13 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
12-15 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  12-15 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  12-15 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  12-15 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
16 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-19 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16-19 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
19 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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